In this issue:
Nivolumab vs. sorafenib in advanced HCC
Common genetic variations in alcohol-related HCC
Prognostic value of baseline imaging and clinical features in advanced HCC
Global, regional and national primary liver cancer burden by subtype
Disparities in palliative care provision for metastatic HCC
Menopausal hormone therapy and biliary tract cancer risk
All-cause HCC survival in the era of DAAs
Serum α-fetoprotein level for predicting HCC occurrence after HCV
Adding ICI to lenvatinib prolongs survival in sorafenib-experienced HCC
Please login below to download this issue (PDF)